Zelluna Immunotherapy has been established based on unique science from the Norwegian Radium Hospital in cell based research and development within the area of immuno-oncology. Birk Venture together with The Norwegian Radium Hospital Research Foundation, Ro invest and the Founders of the technology are the main shareholders in the Company.
